Paclitaxel Releasing Peripheral
Balloon Dilatation Catheter
The revolutionary efficacy in SFA and BTK revascularization!
LEGFLOW RX/OTW provides a 100% anti-proliferative vessel wall protection,
and promotes rapid healing after mechanical balloon angioplasty.
The best option for SFA/popliteal de novo and restenotic lesions.
Treating peripheral artery disease (PAD) in the superficial femoral artery (SFA) is a difficult challenge. The anatomy is very dynamic and contains complex lesions, but also patient comorbidities such as diabetes require the clinically most-effective therapy. The new LEGFLOW Paclitaxel-releasing peripheral balloon dilatation catheter provides a clinically most successful treatment of peripheral artery disease, and ensures a long-term vessel patency.
Please learn more about the excellent and clinically outstanding patient results, which are demonstrated and published by the RAPID Multi-center clinical study program.
The new treatment of BTK lesions and critical limb ischemia! LEGFLOW shows promising early clinical study results.
The rate of recurrent stenosis after PTA and stenting is higher in the below-the-knee area than in femoropopliteal procedures. The absence of metal struts makes the LEGFLOW balloon dilatation suitable for treating long lesions, especially in small diameter vessels and areas in which flexion and compression of the stent may occur and result in stent fractures, particularly in the below-the-knee area. Thanks to the new stable ‘SAFEPAX’ PTX coating technology, the treatment of critical limb ischemia patients appears as safe as POBA angioplasty.Clinical cases
Proven! Optimal therapeutic drug-in-tissue bioavailability resulting
in maximal clinical efficacy.
No signs of vessel toxicity were found. No other safety concerns were noted in animals studied for up to 90 days.*
A short-term balloon-to-vessel wall contact time of 90-120 sec. is sufficient to inhibit SMC proliferation sustainably for up to 150 hours.
Pre-clinical results confirm no noticeable embolization results similar to POBA. Pre-clinical study results confirm a most effective drug delivery into the vascular tissue, showing a sustained drug effect of up to 28 days. ‘Cardionovum’s DCB shows great effectiveness in neo-intimal growth reduction in diseased vessels.’
*Source: Report on pre-clinical studies performed
at CV-PATH Institute (R. Virmani MD), Gaithersburg USA
LEGFLOW SAFEPAX performance. Effective DCB PTX drug-transfer.
Consistent and predictable drug delivery to the artery lesion site results in a homogenous and maximized drug absorption into the arterial tissue.
Only the smallest PTX crystals appear safe enough to bear no risk of adverse embolic or thrombotic effects or obstructing the smaller distal vasculature. LEGFLOW ensures a high patient safety by non-visible 0.1µm smallest PTX particulates leapfrogging ahead of 2.0-3.0µm large Paclitaxel crystals on most other DCBs.
The widest selection of balloon sizes on the market.
The best option for a successful treatment of any SFA and BTK indication.
Treatment of SFA:
4.0 mm - 10.0 mm balloon diameter
1350 mm catheter length
Treatment of BTK:
2.0 mm - 4.0 mm balloon diameter
1500 mm catheter length